Vivione Biosciences | RAPID-B Technology
Vivione Biosciences is powered by RAPID-B technology, an integrated system of hardware, software and wetware that tests bacteria in key environments.
Our mission is to revolutionize the clinical and medical fields, food and industrial safety, water safety and biodefense by utilizing one compact, universal platform for all diagnostic testing that can be used for bacteria, viruses and toxins.
Taking the place of outdated culture-based, immunology-based and molecular-based methods that take countless hours and many times, days, RAPID-B provides more accurate results for each of these fields in minutes to a few hours.
Our technology has combined flow cytometry with our own proprietary reagents to achieve a single cell detection capability in minutes. Unlike culture-based methods, the RAPID-B system does not require isolation of bacteria. It works with the background interference from complex matrices like food.
- Life Sciences
The ARK Challenge startup accelerator last week concluded its fourth installment, and first in Little Rock, with Demo Day presentations of company pitches held inside the Clinton Center's Great Hall.
The museum closed in August to begin remodeling and adding exhibits and new features, thanks to a $7.8 million grant from the Donald W. Reynolds Foundation.
RxResults, a pharmacy risk management company that is partly owned by the University of Arkansas for Medical Sciences, said it plans to add between 20 and 30 jobs in the next 21 months, according to a UAMS news release. Founded in 2008, RxResults was created to help lower drug costs for employers and their workers while making sure they receive the best medicines available.
A researcher at the University of Arkansas for Medical Sciences has received a $1.5 million grant from the National Institutes of Health to investigate the use of nanoparticles in cancer diagnosis and treatment.